Breaking News Instant updates and real-time market news.

INTC

Intel

$52.19

1.45 (2.86%)

, AVGO

Broadcom

$253.78

6.83 (2.77%)

21:06
03/11/18
03/11
21:06
03/11/18
21:06

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Wall Street Journal reported around 5 pm ET on Friday night that Intel (INTC) has worries about competition from a combined Qualcomm (QCOM) and Broadcom (AVGO) and may consider its own bid for Broadcom. Responding to Reuters following the Journal's report, Intel said it does not comment on "rumors or speculation," adding, "We have made important acquisitions over the past 30 months - including Mobileye and Altera - and our focus is on integrating those acquisitions and making them successful for our customers and shareholders." 2. Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the Odyssey Outcomes trial met its primary endpoint, showing Praluent Injection "significantly reduced" the risk of major adverse cardiovascular events in patients who had suffered a recent acute coronary syndrome event, such as a heart attack. 3. Savara (SVRA) announced the Indie study of Aironite did not meet its primary endpoint of improvement in peak exercise capacity assessed by cardiopulmonary exercise testing, or its secondary endpoints. Following the negative outcome of the Indie study, Savara does not plan to support any new development of Aironite. 4. S&P Dow Jones Indices announced adjustments to the S&P 500, moving Take-Two Interactive Software (TTWO) and SVB Financial Group (SIVB) up from the S&P MidCap 400 to take the places of Signet Jewelers (SIG) and Patterson Companies (PDCO). 5. Campbell Soup (CPB), Altria Group (MO) and Molson Coors (TAP) were three consumer-staples names recommended as investments by Jack Hough of Barron's.

INTC

Intel

$52.19

1.45 (2.86%)

AVGO

Broadcom

$253.78

6.83 (2.77%)

QCOM

Qualcomm

$63.03

1.21 (1.96%)

REGN

Regeneron

$341.70

0.92 (0.27%)

SNY

Sanofi

$40.39

0.39 (0.98%)

CPB

Campbell Soup

$43.61

0.47 (1.09%)

MO

Altria Group

$65.65

0.22 (0.34%)

TAP

Molson Coors

$81.09

0.54 (0.67%)

TTWO

Take-Two

$116.61

3.03 (2.67%)

SIVB

SVB Financial

$270.72

5.56 (2.10%)

SIG

Signet Jewelers

$48.90

1.04 (2.17%)

PDCO

Patterson Companies

$25.29

0.37 (1.48%)

SVRA

Savara

$10.98

-0.28 (-2.49%)

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

  • 18

    Mar

  • 19

    Mar

  • 23

    Mar

  • 25

    Mar

  • 29

    Mar

  • 16

    Apr

  • 17

    Apr

  • 24

    Apr

  • 02

    May

  • 30

    May

  • 24

    Sep

INTC Intel
$52.19

1.45 (2.86%)

02/26/18
BARD
02/26/18
NO CHANGE
Target $60
BARD
Outperform
Intel indicating strong growth outlook for 2018, says Baird
Baird analyst Tristan Gerra said Intel's Data Center Group growth could accelerate this year versus last year, fueled by continued strong demand while Xeon Scalable's adoption rate continues to increase. The company also sees a strong second half 2018 outlook for CCG as its momentum will be driven by a sharp rebound in iPhone units and the company's significant share gain. Gerra reiterated his Outperform rating and $60 price target on Intel shares.
02/27/18
SBSH
02/27/18
NO CHANGE
SBSH
Buy
Citi calls Intel the Micron of 2018, moves to top Semi pick
Intel (INTC) is one of the only Semiconductor stocks with poor investor sentiment given its valuation discount to peers and the stock's underperformance year-to-date, Citi analyst Christopher Danely tells investors in a research note. The analyst believes the recovery in the enterprise end market will drive consensus estimates higher. Intel's combination of "very low" sentiment and "substantial" upside to consensus estimates is similar to Micron (MU) in 2017, Danely contends. The analyst moves Intel to his to pick in Semiconductors.
02/26/18
NOMU
02/26/18
NO CHANGE
Target $60
NOMU
Buy
Intel price target raised to $60 from $50 at Nomura Instinet
Nomura Instinet analyst Romit Shah raised his price target for Intel to $60 citing higher estimates and multiple expectations. The analyst notes the company's Datacenter Group revenue exceeded Street expectations for the second consecutive quarter in Q4, growing 20% year-over-year. He believes the growth is sustainable.
03/07/18
KEYB
03/07/18
NO CHANGE
KEYB
KeyBanc remains a buyer of Intel, Marvell
In a research note titled "Notebook ODM tracker," KeyBanc analyst Michael McConnell says February unit shipments are likely to be modestly below his estimates, but is maintaining his Q1 unit shipment estimate of -18% quarter over quarter. McConnell remains a buyer of Intel (INTC) due to its processor sell-in, and signs of improving commercial demand. The analyst also remains constructive on Marvell (MRVL) due to higher confidence on revenue growth, driven by the networking and SSD controller segments, design-win traction and sales momentum into data centers, and higher networking and data center sales mix, gross margin accretion, and multiple expansion from the pending Cavium (CAVM) acquisition.
AVGO Broadcom
$253.78

6.83 (2.77%)

02/22/18
RBCM
02/22/18
NO CHANGE
Target $325
RBCM
Top Pick
RBC finds takeover targets for Broadcom should Qualcomm deal fail
RBC Capital analyst Amit Daryanani finds it prudent to think about other takeover options for Broadcom (AVGO) should its attempt to acquire Qualcomm (QCOM) fail. Broadcom is in a "unique position" as it generates $9B-$10B of free cash flow annually, has balance sheet that is "almost net debt neutral" and a management team "that has impeccable history in integrating assets," Daryanani tells investors in a research note titled "If not QCOM, Who Is Next?" The analyst sees potential targets in Xilinx (XLNX), Analog Devices (ADI), Maxim Integrated (MXIM), Marvell Technology (MRVL) and Microsemi (MSCC). Daryanani keeps a Top Pick rating on Broadcom with a $325 price target. He believes the company has the ability to sustain double-digit growth with or without Qualcomm.
02/21/18
STFL
02/21/18
NO CHANGE
Target $68
STFL
Hold
Stifel sees Broadcom acquisition as unlikely, cuts Qualcomm target to $68
Stifel analyst Kevin Cassidy said earlier that Broadcom's (AVGO) lower offer of $79 per share may concern Qualcomm (QCOM) shareholders and motivate a vote for Broadcom board nominees. He now views the Broadcom acquisition as unlikely given the lower offer and cut his price target on Qualcomm shares to $68 from $82. Cassidy, who added that his "unscientific conversations" with Qualcomm shareholders reveal they are not convinced the company can earn $6.75-$7.50 per share in FY19, keeps a Hold rating on Qualcomm shares.
02/21/18
SUSQ
02/21/18
NO CHANGE
Target $78
SUSQ
Positive
Raised NXP bid bad for Qualcomm shareholders, says Susquehanna
Susquehanna analyst Christopher Roland said the raised bid for NXP Semiconductor (NXPI) by Qualcomm (QCOM) is bad for Qualcomm shareholders as it lowers the chances that the company is ultimately acquired by Broadcom (AVGO). Roland maintained his Positive rating and $78 price target on Qualcomm shares in a note issued prior to Broadcom's announcement that it has lowered its takeover offer for Qualcomm to $79 per share.
03/09/18
OPCO
03/09/18
NO CHANGE
Target $315
OPCO
Outperform
Oppenheimer a long-term buyer of Broadcom ahead of earnings
Oppenheimer analyst Rick Schafer said he is a long-term buyer of Broadcom (AVGO) ahead of the company's Q1 results next week. In a research note to investors, Schafer, who has an Outperform rating and $315 price target on shares, said he believes the potential Qualcomm (QCOM) acquisition remains "in play," a significant upside call option. He sees a "clear path" toward $20 of standalone earnings per share, and said he is a long-term buyer "with or without Qualcomm."
QCOM Qualcomm
$63.03

1.21 (1.96%)

REGN Regeneron
$341.70

0.92 (0.27%)

02/21/18
ADAM
02/21/18
DOWNGRADE
ADAM
Hold
Regeneron downgraded to Hold from Buy at Canaccord
02/21/18
02/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Neutral from Buy at Nomura Instinet with analyst Bill Carcache saying he believes the benefit of improving credit is now fully discounted in the shares and he sees "little room" for positive earnings revisions given the company's slowing sales growth. 2. Lionsgate (LGF.A, LGF.B) downgraded to Market Perform from Outperform at Bernstein with analyst Todd Juenger saying he believes competitive investment from rival premium and SVOD services has gotten much more intense, and notes that increased programming investment at Starz is a necessary but recurring cost of doing business, which means the normalized growth rate for Starz has to be lower. 3. Match Group (MTCH) downgraded to Neutral from Overweight at JPMorgan with analyst Doug Anmuth saying he sees fewer catalysts in the first half of 2018 now that the surge in Tinder Gold has passed. 4. BHP Billiton (BHP) downgraded to Neutral from Buy at Citi with analyst Heath Jansen saying the company's first half of fiscal 2018 results were below expectations. 5. Regeneron (REGN) downgraded to Hold from Buy at Canaccord with analyst John Newman citing concern over the company's decision to not provide guidance for Eylea, which is concerning because it will remain the company's core revenue component for many years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Leerink remains positive on Regeneron/Sanofi Dupixent
Leerink analyst Geoffrey Porges says sentiment about the revenue potential of Regeneron (REGN)/Sanofi's (SNY) Dupixent has been declining over the past year, despite an impressive launch, and a steady flow of data for new indications and populations. The analyst remains positive about the product, forecasting 2020 revenue of $4B and growing to $6.5B by 2022 and $7.8B by 2025 from multiple indications.
02/21/18
ADAM
02/21/18
DOWNGRADE
Target $356
ADAM
Hold
Regeneron downgraded to Hold at Canaccord
As reported previously, Canaccord analyst John Newman downgraded Regeneron to Hold from Buy. The analyst cited concern over the company's decision to not provide guidance for Eylea, which is concerning because it will remain the company's core revenue component for many years. He also noted increasing competition for Dupixent ahead of the expected pediatric market uptick on 2021. Newman lowered his price target to $356 from $522 on Regeneron shares.
SNY Sanofi
$40.39

0.39 (0.98%)

02/08/18
BERN
02/08/18
NO CHANGE
Target $45
BERN
Market Perform
Sanofi price target lowered to $45 from $50 at Bernstein
Bernstein analyst Tim Anderson lowered his price target for Sanofi to $45 from $50 following a "weak" quarter. The analyst reiterates a Market Perform rating on the shares.
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.
CPB Campbell Soup
$43.61

0.47 (1.09%)

02/28/18
PIPR
02/28/18
DOWNGRADE
PIPR
Underweight
Campbell Soup downgraded to Underweight from Neutral at Piper Jaffray
03/01/18
PIPR
03/01/18
DOWNGRADE
Target $45
PIPR
Underweight
Campbell Soup downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery downgraded Campbell Soup to Underweight and lowered his price target for the shares to $45 from $53. The analyst sees multiple expansion as unlikely given his expectations for 1.0%-1.5% earnings growth in fiscal 2019. Higher interest rates and lower than expected Snyder-Lance operating contribution weigh on the analyst's earnings expectations.
03/01/18
03/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Campbell Soup (CPB) downgraded to Underweight from Neutral at Piper Jaffray by analyst Michael Lavery, who sees multiple expansion as unlikely given his expectations for 1%-1.5% earnings growth in fiscal 2019. Higher interest rates and lower than expected Snyder-Lance operating contribution weigh on the analyst's earnings expectations. 2. MannKind (MNKD) downgraded to Sell from Hold at Maxim by analyst Jason Kolbert, who said the company's Afrezza revenues of $4.5M were at the lower end of recently-lowered guidance and were " clearly disappointing given management's robust marketing plans". Kolbert added that the company has just $44M of cash remaining, having burned through about $120M last year. 3. Darling Ingredients (DAR) downgraded to Neutral from Buy at Goldman Sachs by analyst Adam Samuelson. While the company's Q4 results came in modestly above expectations, the analyst finds the outlook for roughly flat EBITDA in the base business despite recent growth investments disappointing. Samuelson sees a less attractive risk/reward for Darling post the Q4 results. Shares were also downgraded to Market Perform from Outperform at BMO Capital by analyst Kenneth Zaslow, who said his undamental view on the company has not changed, pointing to less compelling risk-reward based on limited upside in the stock price and some near-term headwinds. 4. Gibraltar Industries (ROCK) downgraded to Sector Weight from Overweight at KeyBanc by analyst Kenneth Zener, who said the risk to return is currently balanced. The analyst awais clarity on the company's next portfolio addition and wants to sees a "steady cadence of Solar EBIT margins." He believes, however, the Gibraltar is executing well post its Q4 results. 5. Mohawk (MHK) downgraded to Buy from Conviction Buy at Goldman Sachs. Analyst Samuel Eisner removed Mohawk from the Conviction Buy List citing near-term risks from rising rates and 1H18 risks from increasing costs and ramping capacity that could put a lid on shares near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/18
JEFF
02/06/18
DOWNGRADE
Target $50
JEFF
Hold
Snyder's-Lance downgraded to Hold from Buy at Jefferies
Jefferies analyst Akshay Jagdale downgraded Snyder's-Lance (LNCE) to Hold citing the acquisition by Campbell Soup (CPB). The chance of a higher, alternative bid emerging is "fairly remote" given the transaction's rich valuation, Jagdale tells investors in a research note. The analyst raised his price target for the shares to $50 from $44 and expects the deal to close in Q2.
MO Altria Group
$65.65

0.22 (0.34%)

01/19/18
JEFF
01/19/18
UPGRADE
Target $81
JEFF
Buy
Altria Group upgraded to Buy from Hold at Jefferies
Jefferies analyst Owen Bennett upgraded Altria Group to Buy saying he's bullish on Tobacco for fiscal 2018. The analyst sees returns driven by "solid" EBITDA, easing regulatory concerns and benefits from tax reform. He also sees the possibility of large-scale acquisitions adding to the upside. The analyst upped his price target for Altria Group shares to $81.
01/19/18
JEFF
01/19/18
UPGRADE
Target $124
JEFF
Buy
Philip Morris upgraded to Buy from Hold at Jefferies
Jefferies analyst Owen Bennett upgraded Philip Morris to Buy saying he's bullish on Tobacco for fiscal 2018. The analyst sees returns driven by "solid" EBITDA, easing regulatory concerns and benefits from tax reform. He also sees the possibility of large-scale acquisitions adding to the upside. The analyst upped his price target for Philip Morris shares to $124. Bennett this morning also upgraded Altria Group (MO) to Buy. British American Tobacco (BTI) remains his top pick, followed by Altria, then Philip Morris.
01/19/18
01/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Outperform from Neutral at Wedbush analyst Christopher Svezia saying the brand's new footwear styles are "notably higher" versus a year ago while comparisons are easing, particularly around key categories like basketball. 2. Abercrombie & Fitch (ANF) upgraded to Buy from Hold at Argus with analyst John Eade saying the stock has "fallen out of favor" with its core market, but the turnaround strategy implemented by the new CEO, along with the hiring of a Chief Marketing Officer, has produced two consecutive quarter of earnings beats. 3. Chipotle (CMG) upgraded to Market Perform from Underperform at Raymond James with analyst Brian Vaccaro citing fair valuation and no longer sees downside risk given management's decision to take a third and final round of menu price increases and stabilizing industry demand trends. 4. Foot Locker (FL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Kelly Chen saying the worst of the athletic industry's issues have passed. 5. Philip Morris (PM) and Altria Group (MO) were upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/26/18
JEFF
01/26/18
NO CHANGE
JEFF
Buy
Jefferies sees 'big opportunity' in British American Tobacco after selloff
Jefferies analyst Owen Bennett sees a "big opportunity" in shares of British American Tobacco (BTI) following yesterday's selloff. There is a "very strange disconnect here," Bennett tells investors in a research note. The 3.5% pullback doesn't make sense, he adds. He believes that if the market thinks Philip Morris' (PM) IQOS won't get approved, then it is a positive for British American Tobacco. The analyst thinks the selloff can only be explained by holders assuming a Premarket Tobacco Application for IQOS will be approved. Such an approval will likely create support for Philip Morris and Altria Group (MO), Bennett argues. Following conversations in the U.S., the analyst sees a "complete lack of knowledge" around where British American Tobacco stands with heated tobacco approvals. Bennett has Buy ratings on all three stocks.
TAP Molson Coors
$81.09

0.54 (0.67%)

02/08/18
BREN
02/08/18
UPGRADE
Target $76
BREN
Hold
Berenberg not seeing enough downside in Molson Coors, upgrades to Hold
Berenberg analyst Javier Gonzalez Lastra upgraded Molson Coors to Hold from Sell with an unchanged price target of $76. The analyst sees limited downside from the current share price and thinks greater cost savings could be a near-term upside catalyst. The shares may benefit in the short-term from a potential upgrade to management's cost savings target, Lastra tells investors in a research note.
02/12/18
FBCO
02/12/18
UPGRADE
FBCO
Outperform
Molson Coors upgraded to Outperform from Neutral at Credit Suisse
02/12/18
FBCO
02/12/18
UPGRADE
Target $94
FBCO
Outperform
Credit Suisse upgrades 'washed out' Molson Coors to Outperform
Credit Suisse analyst Laurent Grandet upgraded Molson Coors Brewing to Outperform from Neutral and raised his price target for the shares to $94 from $92. The analyst sees a "unique opportunity" this year for the company to use its tax savings to invest in key brands and drive sales growth. He views the stock as "washed out" with a favorable risk/reward amid "very low embedded expectations."
02/08/18
02/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) upgraded to Positive from Neutral at Susquehanna with analyst Rachael Rothman saying the resignation of Steve Wynn removes an overhang. 2. Molson Coors (TAP) upgraded to Hold from Sell at Berenberg with analyst Javier Gonzalez Lastra saying he sees limited downside from the current share price and thinks greater cost savings could be a near-term upside catalyst. 3. Humana (HUM) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying after ceding market share for "several years," Humana should return to above market individual Medicare Advantage enrollment growth in 2019 as it benefits from a favorable rate update and tax reform. 4. Anadarko (APC) upgraded to Outperform from Neutral at Macquarie with analyst Paul Grigel saying he sees sustainable upside into 2018 due to continued strong growth in US production, infrastructure and its advantage in the DJ Basin. 5. Just Energy (JE) was upgraded to Outperformer from Neutral at CIBC and to Buy from Hold at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TTWO Take-Two
$116.61

3.03 (2.67%)

02/09/18
HDLY
02/09/18
UPGRADE
HDLY
Neutral
Take-Two upgraded to Neutral from Underperform at Hilliard Lyons
Hilliard Lyons analyst Jeffrey Thomison upgraded Take-Two to Neutral from Underperform following the company's third quarter report and a subsequent pullback yesterday in the stock.
02/08/18
LEHM
02/08/18
NO CHANGE
Target $128
LEHM
Overweight
Take-Two price target raised to $128 from $121 at Barclays
Barclays analyst Ryan Gee raised his price target for Take-Two Interactive Software to $128 saying the company last night reported a "solid" Q3 earnings beat. The stock could see both multiple expansion and positive estimate revisions into Red Dead Redemption 2, Gee tells investors in a research note. He reiterates an Overweight rating on Take-Two.
02/08/18
BARD
02/08/18
NO CHANGE
Target $137
BARD
Outperform
Baird says buy Take-Two on weakness as fundamentals remain positive
Baird analyst Colin Sebastian noted Take-Two reported solid Q3 results and said the fundamentals remain positive given the digital transition and strong product sales. The analyst expects the shares to trade lower while investors digest the earnings report, but he recommends being a buyer on any weakness. Sebastian reiterated his Outperform rating and $137 price target on Take-Two shares.
02/08/18
WEDB
02/08/18
NO CHANGE
Target $126
WEDB
Neutral
Take-Two price target raised to $126 from $95 at Wedbush
Wedbush analyst Michael Pachter raised his price target for Take-Two to $126 from $95 noting that the company has consistently delivered upside to guidance and consensus, making its shares attractive over the near-term. The analyst reiterates a Neutral rating on the stock due to an unclear long-term release slate.
SIVB SVB Financial
$270.72

5.56 (2.10%)

01/26/18
RHCO
01/26/18
NO CHANGE
Target $300
RHCO
Buy
SVB Financial price target raised to $300 from $280 at SunTrust
SunTrust analyst Jennifer Demba raised her price target on SVB Financial to $300 and kept her Buy rating after Q4 earnings. Demba says the company has more tailwinds than headwinds after one of the best years in 2017,with a strong prospecting effort for core fee income. The analyst notes that SVB Financial should continue to post strong loan growth this year.
01/26/18
FIGP
01/26/18
DOWNGRADE
FIGP
Market Perform
SVB Financial downgraded to Market Perform from Outperform at Fig Partners
01/10/18
MAXM
01/10/18
NO CHANGE
Target $300
MAXM
Buy
SVB Financial price target raised to $300 from $250 at Maxim
Maxim analyst Michael Diana raised his price target on SVB Financial to $300, citing the positive impact from the lower U.S. corporate tax rates. Diana notes that SVB has "one of the highest tax rates among banks" and would benefit from the 21% tax rate reform. The analyst also sees the potential increase in SIFI - systemically important financial institution - threshold to $250B from $50B as incrementally positive for the bank, which is well below that size. Diana keeps his Buy rating on SVB Financial.
01/12/18
PIPR
01/12/18
NO CHANGE
Target $288
PIPR
Overweight
Piper calls SVB Financial 'highest conviction name for 2018'
Piper Jaffray analyst Brett Rabatin calls SVB Financial his "highest conviction name for 2018." The analyst sees SVB shares returning to a significant premium relative to the broader bank space. He thinks the company's loan growth could be more positive than expected and anticipates its net interest margin increasing another 30 basis points in fiscal 2018. Rabatin keeps an Overweight rating on SVB Financial with a $288 price target.
SIG Signet Jewelers
$48.90

1.04 (2.17%)

01/11/18
NEED
01/11/18
NO CHANGE
Target $60
NEED
Buy
Signet Jewelers holiday results were disappointing, says Needham
Needham analyst Rick Patel says the Holiday Sales update from Signet Jewelers was disappointing, as the company "missed an opportunity to capitalize on higher retail industry sales not seen in years". Patel adds that Signet's credit transition continues to pressure comps while the stabilization in credit sales remains unclear. The analyst keeps his Buy rating and $60 price target on the stock, "taking solace" in a strong performance at Zale and e-commerce.
01/12/18
RBCM
01/12/18
DOWNGRADE
Target $55
RBCM
Sector Perform
Signet Jewelers downgraded to Sector Perform at RBC Capital on soft comps
As reported earlier, RBC Capital analyst Brian Tunick downgraded Signet Jewelers to Sector Perform from Outperform and lowered his price target to $55 from $60. Tunick says the latest disappointing holiday season comps are another reminder that his expectations of smoother SSS recovery based on the company's leading market position did not pan out. The analyst notes he is now less confident of share gains in the near term, adding that the sale of the company's subprime book in the first half of this year "could add incremental noise".
01/11/18
WELS
01/11/18
NO CHANGE
Target $52
WELS
Market Perform
Signet Jewelers price target lowered to $52 from $60 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for Signet Jewelers to $52 from $60 to reflect tax reform. The analyst reiterates a Market Perform rating on the shares.
01/12/18
RBCM
01/12/18
DOWNGRADE
RBCM
Sector Perform
Signet Jewelers downgraded to Sector Perform from Outperform at RBC Capital
PDCO Patterson Companies
$25.29

0.37 (1.48%)

03/01/18
03/01/18
DOWNGRADE
Target $24

Underperform
Patterson Companies downgraded to Underperform at Evercore ISI
As previously reported, Evercore ISI analyst Ross Muken downgraded Patterson Companies to Underperform from In Line following quarterly results. The analyst believes that given the uncertainty surrounding dental sales and underlying margin stability, it is hard to get any degree of comfort around the longer-term earnings power of the business. Muken also lowered his price target on the shares to $24 from $38.50.
03/02/18
MSCO
03/02/18
NO CHANGE
Target $20
MSCO
Underweight
Hard to call bottom for Patterson Companies shares, says Morgan Stanley
Morgan Stanley analyst Steve Beuchaw said Patterson Companies' (PDCO) continued share losses and market deterioration make the right multiple "unknowable" and calling the bottom for the stock challenging. His end market tracking and field checks continued to skew negative in recent months, but then Henry Schein's (HSIC) results suggested he was too cautious. However, Patterson's report shows that Henry Schein's execution and DSO positioning obscured an environment that does look tougher overall in Q4, said Beuchaw. He keeps an Underweight rating on Patterson and lowered his price target on the stock to $20 from $31.
03/01/18
EVER
03/01/18
DOWNGRADE
EVER
Underperform
Patterson Companies downgraded to Underperform from In Line at Evercore ISI
03/08/18
LEHM
03/08/18
INITIATION
Target $23
LEHM
Underweight
Patterson Companies initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Patterson Companies with an Underweight rating and $23 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
SVRA Savara
$10.98

-0.28 (-2.49%)

09/22/17
JEFF
09/22/17
INITIATION
Target $20
JEFF
Buy
Savara initiated with a Buy at Jefferies
Jefferies analyst David Steinberg started Savara with a Buy rating and $20 price target. The "under the radar" company aims to be a leader in rare lung diseases, the analyst tells investors in a research note. Savara's lead program molgradex could be the first FDA approved drug to treat the 2,250 Americans suffering from autoimmune pulmonary alveolar proteinosis, he contends.
09/27/17
ROTH
09/27/17
INITIATION
Target $40
ROTH
Buy
Savara reinitiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins re-instated Savara with a Buy rating and $40 price target.
10/31/17
10/31/17
NO CHANGE
Target $32

Buy
Savara price target lowered to $32 from $40 at Roth Capital
As previously reported, Roth Capital analyst Michael Higgins lowered his price target for Savara to $32 from $40 following the company's equity raise. The analyst reiterates a Buy rating on the shares, noting the funds raised will be used to help support development of Molgradex in nontuberculous mycobacterial lung infections, which he calls "an increasingly prevalent" disease.
01/03/18
LTCO
01/03/18
INITIATION
Target $35
LTCO
Buy
Savara initiated with a Buy at Ladenburg
Ladenburg Thalmann started Savara with a Buy rating and $35 price target.

TODAY'S FREE FLY STORIES

02:20
07/17/18
07/17
02:20
07/17/18
02:20
General news
FX Update: The Dollar majors have been holding narrow ranges »

FX Update: The Dollar…

01:50
07/17/18
07/17
01:50
07/17/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap: Long…

01:45
07/17/18
07/17
01:45
07/17/18
01:45
General news
Breaking General news story  »

Federal Reserve Chairman…

PAA

Plains All American

$23.39

-0.14 (-0.59%)

20:30
07/16/18
07/16
20:30
07/16/18
20:30
Periodicals
Plains All American denied tariff exclusion in $1.1B project, Reuters says »

The U.S. Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

COP

ConocoPhillips

$70.59

-1.425 (-1.98%)

20:13
07/16/18
07/16
20:13
07/16/18
20:13
Hot Stocks
ConocoPhillips provides 'strong' outlook for Alaska business »

ConocoPhillips provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

FSUMY

Fortescue Metal

$0.00

(0.00%)

20:08
07/16/18
07/16
20:08
07/16/18
20:08
Upgrade
Fortescue Metal rating change at Citi »

Fortescue Metal upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$112.95

0.23 (0.20%)

, DISH

Dish

$32.75

-0.84 (-2.50%)

20:02
07/16/18
07/16
20:02
07/16/18
20:02
Hot Stocks
PepsiCo to replace Dish in Nasdaq-100 index effective July 23rd »

Nasdaq announced that…

PEP

PepsiCo

$112.95

0.23 (0.20%)

DISH

Dish

$32.75

-0.84 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$26.99

-0.52 (-1.89%)

, CAT

Caterpillar

$138.06

-2.68 (-1.90%)

20:00
07/16/18
07/16
20:00
07/16/18
20:00
Downgrade
Manitowoc, Caterpillar, Deere, Generac rating change at Goldman Sachs »

Manitowoc downgraded to…

MTW

Manitowoc

$26.99

-0.52 (-1.89%)

CAT

Caterpillar

$138.06

-2.68 (-1.90%)

DE

Deere

$136.19

-1.41 (-1.02%)

GNRC

Generac

$52.40

-0.585 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 08

    Aug

CZR

Caesars

$11.63

0.075 (0.65%)

19:33
07/16/18
07/16
19:33
07/16/18
19:33
Hot Stocks
Caesars breaks ground on $375M Caesars Forum in Las Vegas »

Caesars Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

19:25
07/16/18
07/16
19:25
07/16/18
19:25
Conference/Events
Morgan Stanley telecom analyst to hold an analyst/industry conference call »

U.S. Equity Strategist…

CAAP

Corporacion America Airport

$9.87

0.08 (0.82%)

19:11
07/16/18
07/16
19:11
07/16/18
19:11
Hot Stocks
Corporacion America Airport reports June passenger traffic up 5.8% »

Corporacion America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$53.64

-0.36 (-0.67%)

19:08
07/16/18
07/16
19:08
07/16/18
19:08
Hot Stocks
Rio Tinto announces Q2 Pilbara iron ore production 88.5Mt, up 14% from last year »

Pilbara iron ore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

CDMO

Avid Bioservices

$4.46

-0.19 (-4.09%)

, IGT

International Game

$24.39

-0.5 (-2.01%)

19:06
07/16/18
07/16
19:06
07/16/18
19:06
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Avid…

CDMO

Avid Bioservices

$4.46

-0.19 (-4.09%)

IGT

International Game

$24.39

-0.5 (-2.01%)

BGS

B&G Foods

$29.80

-0.2 (-0.67%)

AG

First Majestic

$7.44

-0.265 (-3.44%)

NFLX

Netflix

$400.24

4.32 (1.09%)

ROKU

Roku

$48.27

-0.52 (-1.07%)

AVEO

Aveo Pharmaceuticals

$2.85

-0.055 (-1.90%)

EOLS

Evolus

$25.08

-1.12 (-4.27%)

TRQ

Turquoise Hill

$2.94

0.11 (3.89%)

CARB

Carbonite

$38.40

-0.1 (-0.26%)

RDFN

Redfin

$23.99

0.46 (1.96%)

NAKD

Naked Brand Group

$4.95

-0.15 (-2.94%)

MTW

Manitowoc

$26.99

-0.52 (-1.89%)

AMZN

Amazon.com

$1,822.02

9.02 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 26

    Jul

  • 02

    Aug

  • 02

    Aug

  • 16

    Aug

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

T

AT&T

$31.90

0.24 (0.76%)

18:58
07/16/18
07/16
18:58
07/16/18
18:58
Hot Stocks
Warner Bros.' 'Aquaman' film out in theaters December 21 »

Warner Bros.'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

SBGI

Sinclair Broadcast

$29.10

-3.9 (-11.82%)

, TRCO

Tribune Media

$32.05

-6.55 (-16.97%)

18:57
07/16/18
07/16
18:57
07/16/18
18:57
Hot Stocks
Sinclair Broadcast 'shocked and disappointed' by FCC Chairman Pai's statement »

Sinclair Broadcast Group…

SBGI

Sinclair Broadcast

$29.10

-3.9 (-11.82%)

TRCO

Tribune Media

$32.05

-6.55 (-16.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 06

    Sep

DE

Deere

$136.19

-1.41 (-1.02%)

18:49
07/16/18
07/16
18:49
07/16/18
18:49
Downgrade
Deere rating change at Goldman Sachs »

Deere downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$138.06

-2.68 (-1.90%)

18:49
07/16/18
07/16
18:49
07/16/18
18:49
Downgrade
Caterpillar rating change at Goldman Sachs »

Caterpillar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 08

    Aug

RIO

Rio Tinto

$53.64

-0.36 (-0.67%)

18:48
07/16/18
07/16
18:48
07/16/18
18:48
Hot Stocks
Rio Tinto says FY18 Pilbara shipments will be at upper end of prior forecast »

Rio Tinto states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

NFLX

Netflix

$400.24

4.32 (1.09%)

18:41
07/16/18
07/16
18:41
07/16/18
18:41
Hot Stocks
Breaking Hot Stocks news story on Netflix »

Netflix CEO: Still not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

18:39
07/16/18
07/16
18:39
07/16/18
18:39
Hot Stocks
Breaking Hot Stocks news story on Netflix »

Netflix says debt remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

IBM

IBM

$145.43

-0.48 (-0.33%)

, GRPN

Groupon

$4.70

0.025 (0.53%)

18:32
07/16/18
07/16
18:32
07/16/18
18:32
Periodicals
IBM seeks $166.5M in damages from Groupon in patent lawsuit, Bloomberg says »

IBM (IBM) is requesting…

IBM

IBM

$145.43

-0.48 (-0.33%)

GRPN

Groupon

$4.70

0.025 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

LGF.A

Lionsgate

$25.33

-0.58 (-2.24%)

, LGF.B

Lionsgate

$23.85

-0.69 (-2.81%)

18:30
07/16/18
07/16
18:30
07/16/18
18:30
Hot Stocks
Lionsgate announces Dr. John Malone, Scott Paterson to retire from board »

On July 11, Dr. John…

LGF.A

Lionsgate

$25.33

-0.58 (-2.24%)

LGF.B

Lionsgate

$23.85

-0.69 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

GNRC

Generac

$52.40

-0.585 (-1.10%)

18:30
07/16/18
07/16
18:30
07/16/18
18:30
Downgrade
Generac rating change at Goldman Sachs »

Generac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$26.99

-0.52 (-1.89%)

18:29
07/16/18
07/16
18:29
07/16/18
18:29
Downgrade
Manitowoc rating change at Goldman Sachs »

Manitowoc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

18:27
07/16/18
07/16
18:27
07/16/18
18:27
Hot Stocks
Breaking Hot Stocks news story on Netflix »

Netflix CEO says median…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.